Three-Dimensional Ultrasonography Versus Magnetic Resonance Imaging for Fibroid Mapping: A Cross Sectional Observational Study

NCT ID: NCT05505331

Last Updated: 2022-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-15

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Three-Dimensional Ultrasonography versus Magnetic Resonance Imaging for Fibroid Mapping: A Cross sectional Observational study

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

2\) Introduction: Uterine fibroids are the most prevalent gynecologic tumors, affecting nearly (20-30) % of women in the reproductive age group\[1\] . Approximately 50% of fibroid cases are symptomatic \[2\] and presented by abnormal uterine bleeding, dysmenorrhea, pressure symptoms, infertility, and pregnancy loss\[3\]. Fibroids are myometrium-derived monoclonal smooth muscle cancers and their growth is reliant on estrogen and progesterone levels, thus fibroids usually expand during pregnancy or during the use of combined oral contraceptives, and shrink after menopause\[4\]. Two dimensional ultrasound is the initial test of choice to assess the presence of fibroids in symptomatic patients as it is simple, easy, available and informative \[5\]. Furthermore, ultrasonography may be sufficient for individuals having conservative therapy. However, Magnetic Resonance Imaging (MRI) gives a more precise evaluation of the quantity, location, and type of fibroids specially in cases with considerable uterine enlargement \[6, 7\] and submucosal fibroids. Furthermore, MRI can be utilized to differentiate between fibroids and their imitators, such as adenomyosis, ovarian neoplasms, and localized myometrial contractions \[8\].The introduction of 3D ultrasound in evaluating uterine fibroids appears to be an upcoming and promising prospect \[9\]. However, the evidence on the role of Three-Dimensional Ultrasonography for fibroid mapping is quite limited up till now.

3\) Aim of the study The aim of this study is to compare the accuracy of 3D ultrasound and MRI for fibroid mapping in women with symptomatic fibroids diagnosed by 2D ultrasound.

4\) Subjects and Methods

1. Study type: Cross sectional observational study
2. Inclusion criteria:

• Age group: child bearing period.

• Abnormal uterine bleeding
* Dysmenorrhea
* Pressure symptoms
* Infertility
* Pregnancy loss
3. Exclusion criteria

* The cardiac implantable electronic device (CIED)
* Metallic intraocular foreign bodies
* Implantable neurostimulation systems
* Cochlear implants/ear implant
* Drug infusion pumps
* Cerebral artery aneurysm clips
* Magnetic dental implants
* Artificial limb
4. Methods

* This study is a clinical trial that will include all patients fulfilling the eligibility criteria and presented to the department of Obstetrics and Gynecology in Sohag University hospital (Egyptian tertiary referral hospital) from August 2022 to July 2023. The attending physician will explain the nature of the study and all patients will be asked to sign an informed consent. All patients underwent gynecologic and ultrasound examinations, comprising standard 2D followed by 3D ultrasound. For both examinations, a transabdominal and transvaginal US (Voluson,p8) will be used. All symptomatic patients who are diagnosed by conventional 2D scan will be subjected to 3D ultrasound in the mid-cyclic period (late follicular phase) and all the following points will be assessed for fibroid mapping.

o Uterine corpus: Measurement of length, anteroposterior diameter, transverse diameter and volume

o Serosal contour: Regular versus lobulated

o Myometrial walls: Symmetrical versus asymmetrical

o Myometrial echogenicity: Homogeneous versus heterogeneous

o Myometrial lesions Well defined versus ill defined Number Location (anterior, posterior, fundal, right or left lateral, global) Site (type according to FIGO classification) Size (three perpendicular diameters) Outer lesion-free margin (distance from the serosal surface) Inner lesion-free margin (distance from the endometrial surface) Echogenicity (homogeneous versus heterogeneous; hypo-, iso-, hyper-echogenic)
* Sonographic evaluation will be done by the same gynecologist to avoid interpersonal variability.

Then all the patients will be subjected pelvic MRI at the radiology department in Sohag University hospital and all cases will be evaluated by the same radiologist using the proper MRI protocol including multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane. Then we will compare the 3D ultrasonographic evaluation and the MRI fibroid mapping with the definite intraoperative findings and retrospectively evaluate the impact of this evaluation on the selected surgical intervention.
5. Diagnosis of Fibroids by 3D-ultrasonography • This technology captures serial consecutive 2D pictures in three planes: axial, horizontal, and perpendicular. The 2D slice thickness, which may be modified in increments of 2, 4, or 8 mm depending on the individual needs of each investigation, is then translated into volume data, which can subsequently be saved and analyzed in various angles and arbitrary planes\[10\] . 3D US also offers an accurate coronal view of the uterus, which aids in the delineation of fibroid extension inside the myometrium and into the endometrial cavity. It also depicts the extent and grade of cavity distortion.

3\) Outcome measures:

1. Primary

• The sensitivity and specificity of the 3D-Ultrasonography and MRI for the mapping of different types of symptomatic uterine fibroids according to the final intraoperative diagnosis.
2. Secondary • The validity of 3D-ultrasonography and MRI of Fibroids for selecting the appropriate way of management.

5\) Statistical analysis: This is a cross sectional study that will include all eligible patients from August 2022 to July 2023. Case by case analysis will be done to test the sensitivity and specificity of each 3D ultrasonographic marker and MRI for fibroid mapping in comparison to final intraoperative findings. Data will be expressed as mean ± standard deviation (SD), unless stated otherwise. Chi-squared test will be used to compare categorical variables and Student's t-test to compare continuous variables. A p-value of \<0.05 will be considered statistically significant. STATA v14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) and MedCalc programs and will be used for data analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Three-Dimensional Ultrasonography Versus Magnetic Resonance Imaging for Fibroid Mapping

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

three-Dimensional ultrasonography

transadominal and transvaginal examination

Intervention Type RADIATION

Magnetic resonance imaging

multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane

Intervention Type RADIATION

myomectomy

myoma excision

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Age group: child bearing period.

* Abnormal uterine bleeding
* Dysmenorrhea
* Pressure symptoms
* Infertility
* Pregnancy loss

Exclusion Criteria

* • The cardiac implantable electronic device (CIED)

* Metallic intraocular foreign bodies
* Implantable neurostimulation systems
* Cochlear implants/ear implant
* Drug infusion pumps
* Cerebral artery aneurysm clips
* Magnetic dental implants
* Artificial limb
Minimum Eligible Age

12 Years

Maximum Eligible Age

52 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mahmoud Ahmed Abdelmawgoud

mahmoud abdelMawjud

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag University Hospital

Sohag, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Bulun SE. Uterine fibroids. N Engl J Med. 2013 Oct 3;369(14):1344-55. doi: 10.1056/NEJMra1209993. No abstract available.

Reference Type BACKGROUND
PMID: 24088094 (View on PubMed)

McLucas B. Diagnosis, imaging and anatomical classification of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008 Aug;22(4):627-42. doi: 10.1016/j.bpobgyn.2008.01.006. Epub 2008 Mar 7.

Reference Type BACKGROUND
PMID: 18328787 (View on PubMed)

Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen F. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol. 2002 Mar;186(3):409-15. doi: 10.1067/mob.2002.121725.

Reference Type BACKGROUND
PMID: 11904599 (View on PubMed)

Hossain MZ, Rahman MM, Ullah MM, Mukthadira M, Akter FA, Jahan AB, Jahan F. A Comparative Study of Magnetic Resonance Imaging and Transabdominal Ultrasonography for the Diagnosis and Evaluation of Uterine Fibroids. Mymensingh Med J. 2017 Oct;26(4):821-827.

Reference Type BACKGROUND
PMID: 29208870 (View on PubMed)

Murase E, Siegelman ES, Outwater EK, Perez-Jaffe LA, Tureck RW. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics. 1999 Sep-Oct;19(5):1179-97. doi: 10.1148/radiographics.19.5.g99se131179.

Reference Type BACKGROUND
PMID: 10489175 (View on PubMed)

Saravelos SH, Jayaprakasan K, Ojha K, Li TC. Assessment of the uterus with three-dimensional ultrasound in women undergoing ART. Hum Reprod Update. 2017 Mar 1;23(2):188-210. doi: 10.1093/humupd/dmw040.

Reference Type BACKGROUND
PMID: 28007752 (View on PubMed)

Salim R, Lee C, Davies A, Jolaoso B, Ofuasia E, Jurkovic D. A comparative study of three-dimensional saline infusion sonohysterography and diagnostic hysteroscopy for the classification of submucous fibroids. Hum Reprod. 2005 Jan;20(1):253-7. doi: 10.1093/humrep/deh557. Epub 2004 Oct 21.

Reference Type BACKGROUND
PMID: 15498782 (View on PubMed)

Deshmukh SP, Gonsalves CF, Guglielmo FF, Mitchell DG. Role of MR imaging of uterine leiomyomas before and after embolization. Radiographics. 2012 Oct;32(6):E251-81. doi: 10.1148/rg.326125517.

Reference Type RESULT
PMID: 23065174 (View on PubMed)

Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003 Jan;188(1):100-7. doi: 10.1067/mob.2003.99.

Reference Type RESULT
PMID: 12548202 (View on PubMed)

Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981 Oct;36(4):433-45. doi: 10.1016/s0015-0282(16)45789-4.

Reference Type RESULT
PMID: 7026295 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-22-08-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Use of Doppler to Diagnose Myometrial Masses
NCT01833871 UNKNOWN PHASE2/PHASE3